Our results suggest that our formulation, prepared using the Fmoc-FF building block and TWEEN®60 and SPAN®60 as stabilizing surfactants, can selectively reach specific cancer cell populations, and similarly, that the delivery of cargo (like diagnostic and/or therapeutic agents) via Fmoc-FF nanogels is saturable and influenced by serum components, represented in our case by circulating serum HSA. The gene discussed is ALB; the disease is cancer.